AzTrials
AzTrials

Rotavirus InfectionPhase 4NCT01266850

Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules

A Phase 4 study testing Rotarix® and RotaTeq® in people with Rotavirus Infection, run by National Institute of Allergy and Infectious Diseases (NIAID) at 13 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Rotavirus, sometimes called the "stomach flu," is the most common cause of severe diarrhea in children. Vaccines can prevent many types of infections and work by causing the body to make proteins called antibodies that fight infection. Read more about this study

Who is it for?
Ages 6 to 14 weeksHealthy volunteers can take part
Conditions the study is for
Rotavirus Infection
What is being tested?
Rotarix® and RotaTeq®
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,384 participants
Where
13 sitesUnited States
Study dates
Mar 2011to Mar 2014
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 14 weeks
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Male or female infants who are at least 6 weeks of age and no more than 14 weeks, 6 days of age at Visit 1.
  • Parent(s)/legal guardian(s) have signed informed consent documents.
  • Children who will be available for the entire study period and whose parents/legal guardians can be reached by telephone.
  • Healthy infants as determined by medical history and by a baseline physical examination with no clinically significant abnormal findings within 14 days before the first dose.
  • Parents/legal guardians able to complete all relevant study procedures during study participation.

Who cannot join

  • Any clinically significant history of gastrointestinal disease including abdominal surgery or liver disease or other serious medical conditions as determined by the site investigator.
  • Any history of immunodeficiency in the infant (e.g., the infant is known to be human immunodeficiency virus (HIV) positive, to have hypogammaglobulinemia, or to have an underlying malignancy), or any infant with any unvaccinated household contact who is immunocompromised such as:
  • Any malignancies or are otherwise immunocompromised;
  • Primary immunodeficiency; or
  • Receiving immunosuppressive therapy.
  • Known sensitivity to any vaccine components, such as latex in the Rotarix® applicator.
Show all 17Show fewer
  • Previous receipt of a rotavirus vaccine.
  • Acute illness at the time of vaccine administration, such as any of the following within the past 48 hours:
  • Axillary temperature of 100.4 degrees Fahrenheit or higher, or
  • More than 3 grossly watery stools, or
  • Any episodes of vomiting (forceful expulsion of partially digested milk/food). Infants with previous diagnoses of gastroesophageal reflux whose regurgitation episodes have not changed in the 48-hour period prior to the first vaccination may be enrolled.
  • If these symptoms clear within 48 hours and the subject meets the other inclusion/exclusion criteria, then the subject may be enrolled.
  • The subject is currently participating in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication) or has received an experimental agent within 1 month prior to enrollment in this study, or expects to receive another experimental agent during participation in this study.
  • Less than 37 weeks gestation at birth.
  • Receipt of blood and/or blood products (including immunoglobulin) within 4 weeks before vaccine administration.
  • Receipt of live vaccine within the past 30 days or a nonreplicating, inactivated, or subunit vaccine within the last 14 days, although planned licensed trivalent inactivated influenza vaccine that may be administered to children over 6 months of age during a routine clinic visit is permitted and would not be exclusionary.
  • The subject has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.

Trial locations and contacts

13 sites in 1 country.

13 sites in 1 country

United States13 sites

  • Emory Children's Center - Pediatric Infectious Diseases

    Atlanta, Georgia, 30322-1014

  • University of Maryland School of Medicine - Center for Vaccine Development - Baltimore

    Baltimore, Maryland, 21201-1509

  • Duke Translational Medicine Institute - Clinical Vaccine Unit

    Durham, North Carolina, 27704-2120

  • The University of Texas Medical Branch - Sealy Center for Vaccine Development (SCVD)

    Galveston, Texas, 77555-1121

  • Baylor College of Medicine - Molecular Virology and Microbiology

    Houston, Texas, 77030-3411

  • University of Iowa - Vaccine Research & Education Unit

    Iowa City, Iowa, 52242-2600

  • Children's Mercy Hospital and Clinics - Infectious Diseases

    Kansas City, Missouri, 64108-4619

  • Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center

    Nashville, Tennessee, 37232-2573

  • Kaiser Permanente Vaccine Study Center

    Oakland, California, 94612-3610

  • Children's Hospital & Research Center Oakland - Primary Care Clinic

    Oakland, California, 94618-1033

  • Primary Physicians Research Inc. - Pittsburgh

    Pittsburgh, Pennsylvania, 15241-3100

  • Group Health Research Institute - Seattle

    Seattle, Washington, 98101-1466

  • Seattle Children's Hospital - Infectious Diseases

    Seattle, Washington, 98105-3901

Other trials in United States

About this study

Official title: Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules With RotaTeq® and Rotarix®

Rotavirus, sometimes called the "stomach flu," is the most common cause of severe diarrhea in children. Vaccines can prevent many types of infections and work by causing the body to make proteins called antibodies that fight infection. For some vaccines, more than one vaccination is needed so that the body will make enough antibodies to fight infection. The vaccines (RotaTeq® or Rotarix® oral vaccines) given in this study are recommended for infants by the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). These vaccines require either 2 or 3 vaccinations to be effective. Healthy infants between 6 weeks and 14 weeks, 6 days of age at Visit 1 will participate for about 10-12 months. Study procedures include reaction assessment and blood sample.

Read the detailed description

Rotavirus is the most common cause of severe gastroenteritis among children. The purpose of the proposed study is to determine the non-inferiority and safety of the 2 licensed rotavirus vaccines when both are administered to the same child during sequential vaccinations. Both Rotarix® and RotaTeq® vaccines have been evaluated for safety and efficacy in placebo-controlled trials with more than 70,000 infants each and it is likely that both vaccines delivered in various combinations will be safe and effective. Since RotaTeq® was licensed in the United States (US) in 2006, approximately 6 million doses have been administered in the US. In addition, Rotarix® has been licensed in over 100 nations worldwide and has been delivered to many children in Latin America where it has been recommended for universal vaccination for over 2 years. Now both RotaTeq® and Rotarix® are licensed in the US, and it is expected that health care providers will administer both vaccines. A 3-dose regimen is recommended for RotaTeq® and a 2-dose regimen for Rotarix®. From previous experience, it is likely that one of the vaccines may become unavailable for some period or pediatric offices may switch from one vaccine to the other. Thus, it is probable that mixed schedules will be administered to infants. The primary objective is to determine if the proportion of seroresponders in the sequential mixed rotavirus vaccine groups (RotaTeq® and Rotarix®) is non-inferior to the proportion of seroresponders in the recommended schedule of the single vaccine alone group. Secondary Objectives are: to determine the neutralizing rotavirus antibody responses to the most common rotavirus serotypes (G1-G4 and G9) at 3-6 weeks after the last vaccination for both the sequential, mixed rotavirus vaccine schedule and the single rotavirus vaccine recommended schedule; and to determine if sequential mixed rotavirus vaccine schedules are safe with no statistically significant increase in fever, diarrhea, vomiting, or intussusception in the mixed schedule groups when compared with the recommended schedule of the single vaccine alone group. Normal healthy full-term infants who are scheduled to receive their routine infant immunizations and who are at least 6 weeks of age and no more than 14 weeks, 6 days of age at Visit 1 will be recruited from their primary care clinic. Infants will be randomized (open label) to one of 5 different rotavirus vaccine study groups. Two study groups will be administered the standard RotaTeq® or Rotarix® vaccines as 3 and 2 doses, respectively, and 3 study groups will be administered mixed sequences of RotaTeq® and Rotarix® given as 3 doses. All rotavirus vaccines will be administered concurrently with the other routinely administered childhood vaccines. Parents/legal guardians will be given a memory aid and a thermometer, and asked to record any suspected fever (with measured temperature documented) or adverse events for Days 1-8 after vaccination. At approximately 1 week after vaccination, study personnel will contact the parents/legal guardians, review the completed memory aid, and record the findings on the case report form. Blood for immunogenicity testing will be obtained 3-6 weeks after the last dose of vaccine. For the four 3-dose rotavirus vaccine study groups, blood will be obtained at approximately 7 months of age (3-6 weeks after the last rotavirus vaccine dose). For the single Rotarix® vaccine study group, blood will be obtained at approximately 5 months of age (3-6 weeks after the last dose of Rotarix® vaccine). The primary analysis will be based on rates of induction of anti-rotavirus serum immunoglobulin (Ig) A in the 5 study groups 3-6 weeks

Being tested
Rotarix®, RotaTeq®
Keywords
vaccine, rotavirus, gastroenteritis, infants
Medical subject headings
Rotavirus Infections, Gastroenteritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Rotarix®Biological

    Each 1-mL dose of Rotarix® contains a suspension of at least 10^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.

  • RotaTeq®Biological

    2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.

Study groups in NCT01266850
Study groupRoleWhat they receive
Group 1, RotaTeq® x 3Active comparator2, 4 and 6 months of age: RotaTeq®
Receives: Biological: RotaTeq®
Group 5, Rotarix®, RotaTeq® x2Experimental2 months of age: Rotarix®; 4 and 6 months of age: RotaTeq®
Receives: Biological: Rotarix®; Biological: RotaTeq®
Group 4, Rotarix® x 2Active comparator2 and 4 months of age: Rotarix®
Receives: Biological: Rotarix®
Group 2, RotaTeq®, Rotarix® x 2Experimental2 months of age: RotaTeq®; 4 and 6 months of age: Rotarix®
Receives: Biological: Rotarix®; Biological: RotaTeq®
Group 3, RotaTeq® x 2, Rotarix®Experimental2 and 4 months of age: RotaTeq®; 6 months of age: Rotarix®
Receives: Biological: Rotarix®; Biological: RotaTeq®

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay

    Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the anti-rotavirus IgA antibody titer. A participant met the threshold of a positive response if the post vaccination anti-rotavirus IgA antibody titer was 20 or greater.

    Measured: 3-6 weeks after the last vaccination

  2. Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the 89-12 IgA Assay

    Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA 89-12 assay to determine the anti-rotavirus IgA antibody titer. A participant met the threshold of a positive response if the post vaccination anti-rotavirus IgA antibody titier was 20 or greater.

    Measured: 3-6 weeks after the last vaccination

  3. Geometric Mean Serum Anti-rotavirus IgA Titer

    Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the anti-rotavirus IgA antibody titers. The geometric mean titers (GMT) for each group were calculated along with the 95% confidence intervals.

    Measured: 3-6 weeks after the last dose of vaccine

Secondary outcomes (6)

  1. GMT of Neutralizing Rotavirus Antibody to the Most Common Rotavirus Serotypes (G1-G4 and G9)

    Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the neutralizing antibody assay against the most common rotavirus serotypes, G1-G4 and G9. Antigen-specific geometric mean titers (GMT) for each group were calculated along with the 95% confidence intervals.

    Measured: 3-6 weeks after the last dose of vaccine.

  2. Number of Participants Experiencing Solicited Systemic Reactions in the 8 Days After Vaccination

    The participants' parent/guardian was given a memory aid to record for 8 days the presence of solicited reactions of fever, diarrhea and vomiting. Fever was considered experienced if the participant was assessed with an axillary temperature of 100.4F or greater on any day in the 8-day period after any vaccination. Diarrhea was considered experienced if the participant had 3 or more looser than normal stools in a day. Vomiting was considered experienced if the participant vomited 2 or more times in a day.

    Measured: Days 1-8 after each vaccination

  3. Number of Participants Experiencing Hematochezia at Any Time During the Study

    Hematochezia was defined as any stools that are black and tarry; maroon in color; or frank red blood. At each visit, signs of hematochezia were assessed and the participant's parent/guardian was instructed to contact the clinical site at any time if the participant had evidence of hematochezia.

    Measured: Day 1 through 6 months after the last vaccination

  4. Number of Participants Developing Neutralizing Rotavirus Antibody to Rotavirus Serotypes G1, G2, G4P6 and G9

    Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the antibody titers to rotavirus serotypes G1, G2, G4P6 and G9. A participant met the threshold of a positive response if the post vaccination antigen-specific antibody titer was 10 or greater.

    Measured: 3-6 weeks after the last dose of vaccine.

  5. Number of Participants Developing Neutralizing Rotavirus Antibody to Rotavirus Serotype G3

    Blood was collected from all participants prior to vaccination and at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the antibody titers to rotavirus serotype G3. A participant met the threshold of a positive response if the post vaccination antibody titer was 10 or greater.

    Measured: 3-6 weeks after the last dose of vaccine.

  6. Number of Participants Developing Neutralizing Rotavirus Antibody to Rotavirus Serotypes G4P8

    Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the antibody titers to rotavirus serotype G4P8. A participant met the threshold of a positive response if the post vaccination antibody titer was 10 or greater.

    Measured: 3-6 weeks after the last dose of vaccine.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Dec 2010 (estimated)
  2. Study startMar 2011
  3. Primary completionOct 2013
  4. Study completionMar 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,384 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01266850
Sponsor's protocol ID
08-0017
Other IDs
N01AI80006C
Status last verified
Sep 2014
First submitted
23 Dec 2010
Last updated
28 Oct 2014

Publications

  • Libster R, McNeal M, Walter EB, Shane AL, Winokur P, Cress G, Berry AA, Kotloff KL, Sarpong K, Turley CB, Harrison CJ, Pahud BA, Marbin J, Dunn J, El-Khorazaty J, Barrett J, Edwards KM; VTEU Rotavirus Vaccine Study Work Group. Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. Pediatrics. 2016 Feb;137(2):e20152603. doi: 10.1542/peds.2015-2603. Epub 2016 Jan 28.

    PubMed 26823540

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Rotarix® and RotaTeq® in people with Rotavirus Infection, run by National Institute of Allergy and Infectious Diseases (NIAID) at 13 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Oct 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 13 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 28 Oct 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay (time frame: 3-6 weeks after the last vaccination). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01266850, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2014.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in